EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS‐CoV‐2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study

Junyi Sun, Mengzhao Yang, Guanyue Su, Ling Wang, Xiaobo Hu, Yongjian Zhou, Guangying Cui, Guowu Qian, Yiqiang Yuan, Xinjun Hu, Silin Li, Hong Luo und 7 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202405679 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Advanced Science, 2025. Verfasst von Junyi Sun und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou Universit…. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19, COVID-19 Drug Treatment, Liver Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Henan Province Epidemic Prevention and Control Emergency Scientific Research Project, Young and Middle-aged Academic Leaders of Henan Provincial Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite azvudine being prioritized for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, its effectiveness and safety remain inadequately substantiated in hospitalized SARS‐CoV‐2 infected patients with liver diseases. A retrospective nine‐center cohort study along with an independent validation cohort is conducted to examine the efficacy of azvudine (Clinical Trial Registration Number: NCT06349655). The primary outcome is all‐cause mortality and the secondary outcome is composite disease progression. Efficacy is assessed via Kaplan–Meier analysis and Cox regression, with subgroup and sensitivity analyses for further validation. Among 32 864 hospitalized SARS‐CoV‐2 infected patients, 1022 eligible azvudine recipients, and 1022 controls are included through propensity score match. Kaplan–Meier analysis reveals that azvudine treatment is associated with a lower risk of all‐cause mortality and composite disease progression (both p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19COVID-19 Drug TreatmentLiver DiseasesAdultAgedFemaleHumansMaleMiddle AgedDisease ProgressionHospitalizationRetrospective StudiesSARS-CoV-2Treatment Outcome

Stichwörter der Autor:innen

SARS‐CoV‐2all‐cause deathazvudinecomposite disease progressionreal‐world

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
  • Department of Cardiovascular Medicine, Henan Provincial Chest Hospital Affiliated to Zhengzhou University, Zhengzhou, 450008, China.
  • Department of Gastrointestinal Surgery, Nanyang Central Hospital, Nanyang, 473009, China.
  • Department of Infectious Diseases, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, 471003, China.
  • Department of Respiratory and Critical Care Medicine, Fengqiu County People's Hospital, Xinxiang, 453300, China.
  • Guangshan County People's Hospital, Guangshan County, Xinyang, 465450, China.

ORCID-Profile: Zhigang Ren

Förderung

  • National Key Research and Development Program of China
  • Henan Province Epidemic Prevention and Control Emergency Scientific Research Project
  • Young and Middle-aged Academic Leaders of Henan Provincial Health Commission
  • Funding for Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University
  • National Program for Postdoctoral Researchers
  • Joint Construction Project of Henan Medical Science and Technology Research Plan

Zitieren

APA

Sun, J., Yang, M., Su, G., Wang, L., Hu, X., Zhou, Y., Cui, G., Qian, G., Yuan, Y., Hu, X., Li, S., Luo, H., Zhang, S., Li, G., Zhang, D., Li, G., Cheng, M., Yu, Z., & Ren, Z. (2025). The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS‐CoV‐2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study. Advanced Science. https://doi.org/10.1002/advs.202405679

Vancouver

Sun J, Yang M, Su G, Wang L, Hu X, Zhou Y, et al. The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS‐CoV‐2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study. Advanced Science. 2025. doi:10.1002/advs.202405679

BibTeX
@article{Sun2025,
  author = {Sun, Junyi and Yang, Mengzhao and Su, Guanyue and Wang, Ling and Hu, Xiaobo and Zhou, Yongjian and Cui, Guangying and Qian, Guowu and Yuan, Yiqiang and Hu, Xinjun and Li, Silin and Luo, Hong and Zhang, Shixi and Li, Guangming and Zhang, Donghua and Li, Guotao and Cheng, Ming and Yu, Zujiang and Ren, Zhigang},
  title = {The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS‐CoV‐2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202405679}
}
Kostenlos starten →